Digital Therapeutics

Providing these recordings ensures that patients have an accurate to source to reference after a visit with a doctor.

Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.

As the pharma industry relies more and more on smart phones and other connected devices, it's important to remember that not everyone has access to this technology.

Dario set out to determine the effectiveness of deploying adapted machine learning to analyze and personalize user journeys in its DTx posture training solution.

Kaia Back Pain, a digital therapy for the treatment of non-specific acute, subacute and recurrent back pain, has been permanently added to the Directory of Digital Health Applications (DiGA)

ObvioHealth's API provides a tight integration between the digital therapeutic and the ObvioGo platform, providing data that correlates efficacy with adherence to the DTx.

New offering includes a DCT platform bundled with site and trial execution services for the DTx market.

Companies will utilize collaboration to develop prescription digital therapeutics for schizophrenia.

ResearchAndMarkets.com releases "Digital Therapeutics: A New Age Medicine"

Senior leaders focused on the advancement of digital medicine and health meet to discuss the importance of these tools for life sciences companies, payers, and others in harnessing a healthcare future that will be increasingly dominated by holistic treatment and delivery.

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Success in developing patient monitoring and management for melanoma sets stage for expanded partnership.

More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.

As support increases, adoption by Medicare and Medicaid would provide even greater access for patients.

With more promising products emerging, investment risks remain.